Printer Friendly

CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS

 CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE
 USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
 PROVIDENCE, R.I., July 14 /PRNewswire/ -- Dr. Samuel Weiss and Dr. Brent Reynolds of the University of Calgary (Alberta, Canada) and CytoTherapeutics, Inc. (NASDAQ: CTII) announced today that they have signed a collaborative research agreement to investigate the uses of continuously proliferating neural stem cells for use by CytoTherapeutics in cell therapy for the treatment of neurodegenerative disorders.
 CytoTherapeutics' core technology consists of proprietary techniques for encapsulating living cells or tissue within semipermeable polymer membranes. These living cells can then be inserted into the body where they receive nutrients and produce desired therapeutic biomolecules. This technology may allow the therapeutic use of implanted cells that offer advantages over traditional and biotechnology-derived medicines.
 Under the collaborative research agreement, CytoTherapeutics, Inc. has obtained an exclusive evaluation and option agreement from Drs. Weiss and Reynolds for the use of these stem cells in their ongoing research and development for the treatment of neurodegenerative diseases. Further financial terms were not disclosed.
 Initial investigations will involve the implantation of both encapsulated and unencapsulated stem cells and progeny into specific sites within the brain. The goal of this research is to evaluate the potential of these cells to repair or replace compromised neural tissue in central nervous system (CNS) degenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases.
 CytoTherapeutics, Inc. of Providence was formed in 1989 to develop cellular therapies based on proprietary membrane encapsulation technologies acquired from Brown and Washington universities. The company's other product development candidates are its NeuroCRIB(tm) for the treatment of Parkinson's disease, EndoCRIB(tm) for the treatment of Type I diabetes and CereCRIB(tm) for the treatment of severe, chronic pain.
 Dr. Weiss and Dr. Reynolds, of the Neurosciences Research Group at the University of Calgary, Canada, are pioneers in the field of central nervous system stem cell biology, as outlined in their recent article in Science(Vol. 255: 1707).
 -0- 7/14/92
 /CONTACT: Elizabeth Razee, of CytoTherapeutics, 401-272-3310 or Pam Haslam, of Feinstein Partners, 617-577-8110, for CytoTherapeutics/
 (CTII) CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU:


CN -- NE006 -- 9012 07/14/92 10:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1992
Words:365
Previous Article:BAY AREA PRICES REMAINED UNCHANGED IN JUNE -- UP 3.1 PERCENT COMPARED TO JUNE 1991
Next Article:PRIMERICA'S SECOND QUARTER 1992 EPS UP 30 PERCENT TO $1.36 VS. $1.05
Topics:


Related Articles
CELLULAR TRANSPLANTS, INC. CHOOSES NEW NAME, CYTOTHERAPEUTICS, INC.
THOMAS WIGGANS NAMED CHIEF OPERATING OFFICER OF CYTOTHERAPEUTICS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
CYTOTHERAPEUTICS AND NEOCRIN COMPLETE AGREEMENT TO COMBINE DIABETES PROGRAMS
CYTOTHERAPEUTICS OBTAINS EXCLUSIVE, WORLDWIDE LICENSE TO NEURAL STEM CELLS FOR TRANSPLANTATION;
CytoTherapeutics Awarded $4 Million Grant to Advance Cell-Based Therapies for CNS Diseases
CytoTherapeutics Nets $5.5 Million In Sale-Leaseback of New Research Facility
Ceregene announces issuance of patent for gene therapy.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters